RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Luqa Pharma, a Shanghai dermatology and aesthetics company, acquired greater China rights to a novel topical antibiotic aimed at impetigo from Barcelona’s Ferrer. The two companies will collaborate to obtain China approval of Ozenoxacin (known by trade names Ozanex, Dubine and Xepi), which is already approved in the US and EU. Depending on the outcome of the regulatory process, Luqa could exercise a licensing option for further development and commercialization of Ozenoxacin.
Source: China Biotoday
